The Food and Drug Administration has opened the door to a possible regulatory shift on a group of peptide injections that have become wildly popular in wellness, fitness and anti-aging circles, but that remain unapproved as drugs.
In a notice issued Tuesday, the FDA said its Pharmacy Compounding Advisory Committee will meet July 23 and 24 to examine whether seven peptides should be allowed onto the Section 503A bulks list, a step that could eventually permit more licensed compounding pharmacies to make them again for individual patients. The move does not approve the products as safe and effective drugs, and it does not immediately restore broad access.
What the FDA announced is specific and technical, but the implications are broad. The agency said the July 23 session will review BPC-157, KPV, TB-500 and MOTs-C. On July 24, the panel will review emideltide, also known as delta sleeping inducing peptide or DSIP, along with semax and epitalon. The uses FDA says it evaluated for these substances include ulcerative colitis, wound healing, inflammatory conditions, obesity, osteoporosis, opioid withdrawal, chronic insomnia, narcolepsy, cerebral ischemia, migraine and trigeminal neuralgia. The meeting will be public, with written comments accepted through a federal docket.
The issue matters because these substances sit in a legal gray area that exploded into a mainstream wellness craze. Peptides are short chains of amino acids, and some are already well-established medicines — insulin and GLP-1 drugs are examples of FDA-approved peptide therapies. But the seven under review now are among a class of compounds that have been promoted for muscle building, fat loss, injury recovery, reduced inflammation, better sleep and longevity, even though many of those uses are not backed by the kind of clinical evidence the FDA normally requires for approved drugs. These substances have become popular with wellness influencers, biohackers and some celebrities despite limited data on safety and effectiveness.
The backdrop to Tuesday’s move is the FDA’s 2023 crackdown. The agency barred compounding pharmacies from manufacturing 14 peptides in 2023 under the Biden administration because of concerns about immunogenicity, toxicity, impurity and lack of sufficient human testing. The FDA’s own safety-risk page, which still listed several of the peptides under Category 2 at the time of the official page snapshot available through the agency’s site, says BPC-157, emideltide, epitalon and MOTs-C, among others, may pose significant safety risks because of factors such as immunogenicity, peptide-related impurities and the lack of enough human safety information to know whether they would cause harm.
That is why Tuesday’s development is significant but narrower than many social media claims. The FDA has not approved BPC-157, semax, epitalon or the other peptides under review as prescription drugs. The agency has also not yet said compounding pharmacies are free to resume widespread production. Any broader change would still require a formal regulatory process, and another meeting is expected in early 2027 to review additional peptides. In other words, the FDA has started a reconsideration process, not issued a blanket green light.
Still, the move is a major political and policy victory for Health and Human Services Secretary Robert F. Kennedy Jr., who has been publicly pushing easier access to peptides. Kennedy has personally endorsed peptide use, and has argued that Americans should be able to obtain such products through regulated compounding pharmacies rather than from an online or overseas black market. Kennedy told Joe Rogan in February, “I’m a big fan of peptides,” and said he had used them himself with good results for injuries.
Critics say the FDA is moving toward a dangerous loosening of standards. AP reported that former FDA officials and public health experts worry the agency could be opening the door to products that have not been adequately vetted for safety or effectiveness, including some that have been linked in agency reviews or outside concern to organ damage, cancer risk or other serious adverse outcomes. The core argument from critics is that popularity and demand should not substitute for the traditional evidence required for drug approval. Supporters counter that regulated compounding would be safer than the unregulated peptide market that already exists.
Advertisements
